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Abstract
Background: Self-reported antiretroviral therapy (ART) adherence measures that are associated with plasma viral
load (VL) are valuable to clinicians and researchers, but are rarely examined among groups vulnerable to dropping
out of care. One-seventh of all those living with HIV pass through incarceration annually and criminal-justice (CJ)
involved people living with HIV (PLH) are vulnerable to falling out of care. We examined the association of self-
reported ART adherence with VL in a criminal-justice sample compared to a routine-care sample.
Methods: Samples: We examined data from a multisite collaboration of studies addressing the continuum of HIV
care among CjJ involved persons in the Seek, Test, Treat, and Retain cohort. Data pooled from seven CJ- studies (n
= 414) were examined and compared with the routine-care sample from the Centers for AIDS Research Network of
Integrated Clinical Systems’ seven sites (n = 11,698).
Measures: In both samples, data on self-reported percent ART doses taken were collected via the visual analogue
scale adherence measure. Viral load data were obtained by blood-draw.
Analysis: We examined the associations of adherence with VL in both cohorts using mixed effects linear regression
of log-VL, and mixed effects logistic regression of binary VL (≥ 200 copies/mL) outcomes. Interactions by CD4 count
and self-reported health status were also tested.
Results: Among the CJ sample, the coefficient for log-VL was − 0.31 (95% CI = − 0.43, − 0.18; P < 0.01) and that in
the routine-care sample was − 0.42 (95% CI = − 0.45, − 0.38; P < 0.01). For the logistic regression of binary detectable
VL on 10% increments of adherence we found the coefficient was − 0.26 (95% CI = − 0.37, − 0.14; P < 0.01) and in
the routine-care sample it was − 0.38 (95% CI = − 0.41, − 0.35; P < 0.01). There was no significant interaction by CD4
count level in the CJ sample, but there was in the routine-care sample. Conversely, there was a significant
interaction by self-reported health status level in the criminal-justice sample, but not in the routine-care sample.
Conclusions: The visual analogue scale is valid and useful to measure ART adherence, supporting treatment for CJ-
involved PLH vulnerable to falling out of care. Research should examine adherence and VL in additional
populations.
Keywords: Antiretroviral therapy, Medication adherence, Viral load, Incarceration, Criminal justice-involved
populations (5 key words)
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Background
A high level of adherence to antiretroviral treatment
(ART) is essential for achieving viral suppression among
people living with HIV, and is critical for both maintain-
ing their health and preventing HIV transmission to
others. Valid, yet practical measures of adherence to
ART are needed for studies of intervention efficacy and
effectiveness in low-resource settings, and are useful for
the clinical care of hard-to-reach populations who have
extensive barriers to achieving viral suppression. Real-
world, self-reported ART adherence measures that are
reliably associated with viral load (VL) measures provide
many advantages over medication event monitoring
system (MEMS) or pill count, namely increased feasibil-
ity of use in busy clinical care settings where pill counts
and MEMS have numerous logistical hurdles for rou-
tine use, as well as lower costs and more complete
data [1, 2]. Self-report data, however, often underesti-
mate real-world adherence and are susceptible to
recall and social desirability bias [3, 4]. These weak-
nesses may be particularly problematic among those
with substance use disorders, mental illness, low in-
come or lower education/literacy levels, and/or un-
stable housing, which are common among criminal
justice-involved persons [5–9].
As 1 in 7 people living with HIV cycle through crim-
inal justice settings each year [10], clinicians may benefit
from self-reported ART adherence measures that correl-
ate well with viral suppression among the criminal
justice-involved persons they may treat. In this popula-
tion, frequent measurement of VL is challenging, espe-
cially among those recently released from criminal
justice settings who often are out of clinical care [5, 7, 8,
11]. Self-reported adherence is an important and prac-
tical tool to use in HIV care or interventions that help
patients to attain VS. It can be used to identify adher-
ence challenges early, before virologic failure is detected
using VL testing. Few, if any, previous studies have ex-
amined the association of self-reported adherence with
plasma VL among criminal justice-involved persons in
multiple U.S. sites.
One of the most widely used measures of self-reported
adherence is a single-item, 0–100% rating scale, gener-
ally called the visual analogue scale (VAS) [12, 13]. It
has the advantages of brevity, ease of administration
even among low literacy populations, and ease of inter-
pretation. In usual care settings, evidence supports the
validity of VAS for measuring ART adherence, and its
practicality compared with longer self-report measures
or with more objective measures – such as MEMS Caps
or unannounced pill counts (UPC) [14–16]. This single-
item assessment is also easier and briefer than other
self-report measures [13]. The VAS adherence measure
has been shown to be associated with MEMS Caps,
UPC, and viral suppression in some studies [4, 17], but
has not been examined across studies of criminal
justice-involved populations in need of HIV care.
Although several factors besides ART adherence can
affect viral suppression including persistence on ART
[18], genotypic resistance to ART [19, 20], and pharma-
cokinetics of ART medications [21–23], self-reported ad-
herence should be closely associated with VL level, and
very high adherence (> 95%) should predict VS. [20]
Also, the degree of correspondence between the adher-
ence measure and VL might vary, depending on clinical
factors, such as level of immunosuppression measured
by CD4 count and level of self-reported general health
status [24]. Little is known, however, about how well
self-reported ART adherence measures perform in terms
of its association with VL and levels of viral suppression
in criminal justice-involved populations.
This study had two main goals. First, we sought to
examine rates of ART adherence and viral suppression
among criminal justice-involved people living with HIV
across seven sites in the U.S. Second; we aimed to exam-
ine the association between self-reported ART adher-
ence and VL. Additionally, we explored whether the
relationship between adherence and VL was modified by
level of CD4 count or self-reported general health status.
We hypothesized that higher levels of self-reported ART
adherence would be associated with lower levels of VL
or with viral suppression (VL < 200 copies/mL) [25]. In
addition, we hypothesized that the association between
adherence and VL would be stronger among those
reporting worse health or having later stage disease
(lower CD4 count) because patients with more advanced
disease or who have symptomatic HIV are more likely to
both non-adhere to ART and have high plasma HIV
RNA levels [26, 27]. To address these goals, we exam-
ined associations between ART adherence as measured
by the VAS and plasma VL level, using harmonized data
from multiple criminal justice-involved studies across
the U.S. [28]. To provide a normative comparison group,
we examined corresponding measures and associations
among people living with HIV in the Centers for AIDS
Research Network of Integrated Clinical Systems
(CNICS) cohort of people living with HIV in routine,
ambulatory clinical care across multiple sites in the US.
Methods
Design
The current study uses baseline data from seven sites
within the Seek, Test, Treat, and Retain (STTR) cohort
[29], a large, previously described, multi-study collabor-
ation addressing the continuum of HIV care among
criminal justice samples (Table 1). Harmonized data on
people living with HIV pooled from seven individual and
pooled criminal justice-focused studies in the criminal
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justice STTR cohort (n = 414) were compared with data
on people living with HIV pooled from seven CNICS
sites (n = 11,698) [30]. CNICS is a continuously enrolling
cohort study of people living with HIV in routine clinical
care for HIV at multiple sites across the US from 1995
to present. Patient-reported outcomes and laboratory
measures including VL values were collected prior to
visits, directly via tablets or blood draws, respectively, as
part of routine clinical care in CNICS [30]. The data
evaluated in this manuscript was collected from 2011 to
2015 for the STTR cohort and from 2007 to 2017 for
the CNICS cohort as displayed in Table 2.
Study samples
At each study site, baseline interviews and laboratory
measures were collected and processed by individual
studies and the STTR Coordinating Center harmonized
the data. We analyzed and compared cross-sectional,
baseline data from criminal justice-involved people living
with HIV in the STTR studies, and with people living
with HIV in routine care in CNICS. Criminal justice-
involved participants included those in custody or re-
leased but under community supervision. Of 1189 crim-
inal justice-involved (STTR) participants, 414 individuals
had complete data on adherence and VL within 30 days
of the adherence reference period. Of 15,740 possible
people living with HIV in routine clinical care, 11,698
participants had complete data on adherence, or a VL
within 30 days of the adherence reference period.
Measures
In both groups, self-reported adherence data were mea-
sured using the VAS, on a scale of 0–100% of ART doses
taken in the preceding 30 days. Self-reported general
health status was measured using the first item of the
SF-12 instrument (“In general, would you say your
health is: …” ) on a 5-point Likert-type scale with re-
sponse options that ranged from “poor” to “excellent.”
Study sites also collected self-reported data on age and
gender for use in adjusted analyses. We also collected
data on ART regimens – Non-nucleoside Reverse Tran-
scriptase (NNRTI), Protease Inhibitors (PI), integrase
Table 1 Description of Criminal Justice-involved Studies from STTR Cohort [10]
Studies Study Design & Location Targeted Participants
CARE + RCT RCT of CARE+ Corrections intervention;
Washington, DC
Aged 18+; HIV-infected; released from the correctional facility or
half-way house ≤6 months ago and living in Washington, DC
metropolitan community (not a restricted setting, e.g. half-way
house) or currently detained in jail with anticipated release to
community (not a restricted setting); reading at 8th grade level
and English-speaking.
IMPACT RCT of imPACT intervention vs. standard of care;
NC and TX prisons
Aged 18+; HIV-infected with HIV RNA < 400 copies/mL receiving
ART who were incarcerated in NC or TX and 3 months prior to
release and not convicted of sexual assault, death or serious injury;
English-speaking.
LINK LA RCT of intervention; Los Angeles County Jails, CA Men and transgender women, aged 18+; HIV-infected; eligible for
ART, or on ART; jailed for 5+ days, being released to community;
residing in Los Angeles County, CA upon release; English or bilingual
Spanish speaking.
NEW HOPE Double Blind Placebo-controlled RCT of
extended-release naltrexone; New Haven,
Hartford, Waterbury, CT or Springfield, MA
Aged 18+, HIV-infected, meeting DSM-IV criteria for opioid dependence,
within CT & Springfield, MA corrections system and not pending trial for
a felony, within 30 days of being released to greater New Haven, Hartford,
Waterbury or Springfield areas or 30 days after release; English- or
Spanish-speaking, no liver failure or grade IV hepatitis, no active opioid
withdrawal, no receipt of methadone or buprenorphine/naloxone for
treatment of opioid dependency, no participation in pharmacotherapy
trial in the previous 30 days
STRIDE1 RCT of buprenorphine vs. placebo; Washington, DC Aged 18+; HIV-infected; meeting DSM-IV criteria for opioid dependence;
resident of Washington, DC with eligibility for medical entitlements;
English- or Spanish-speaking; no current opiate medications for chronic
pain conditions or need to be placed on such medications; no current
methadone doses over 30 mg/day, no AST and ALT >5x the ULN; no
pregnancy or breast-feeding; no liver dysfunction; no suicidal ideation;
no participation in pharmacotherapy trial in the previous 30 days.
STRIDE2 Longitudinal cohort study comparing treatment
using opioid substitution therapy to no treatment;
Washington, DC
Aged 18+; HIV-infected; meeting DSM-IV criteria for opioid dependence;
resident of Washington DC with eligibility for medical entitlements;
English-speaking.
SUCCESS Non-randomized pilot study of Strengths-Based
case management; Atlanta, GA Jails
Aged 18+; HIV-infected; detained or sentenced in jail or detention center
and likely to leave within 6 weeks; no recent participation in randomized
trial to improve retention in HIV care; English-speaking.
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strand transfer inhibitor (INSTI) [31], and combination
or other ART regimens. Plasma VL and CD4 cell count
data were obtained by each STTR study, thus, there was
not a uniform assay used to measure them. We analyzed
HIV VL as a log transformed (log-VL) continuous meas-
ure, or dichotomized as detectable (≥200 copies/mL) vs.
undetectable (VL < 200 copies/mL) in accordance with
DHHS guidelines [32].
Analysis
Association of VL and ART adherence
We first examined descriptive characteristics of ART ad-
herence and VL, and then assessed the associations of
adherence with VL in each individual criminal justice-
involved study, and the combined criminal justice
sample, which were then compared to the overall,
CNICS, routine HIV care dataset. Next, we constructed
linear and logistic mixed effects regression models with
random intercepts and slopes, adjusted for age using the
criminal justice sample data. To determine the robust-
ness of the associations of adherence with VL, we used
three distinct approaches often used in adherence re-
search [2, 33, 34]. These models examined in criminal
justice-involved persons living with HIV the study-
specific and overall associations of: (A) continuous ad-
herence (10% increments) with continuous log-VL; (B)
continuous adherence (10% increments) in a logistic re-
gression with binary detectable VL; and (C) optimal ad-
herence levels using the VAS (≥95%) predictor in a
logistic regression with binary detectable VL. Because
the separate study sites had relatively small sample sizes,
we used mixed effects models clustered by site to appro-
priately pool study samples, while still allowing for the
possibility that the adherence coefficient had a different
mean value in each study sub-sample. Linear and logistic
regressions adjusted for age, which were also conducted
separately in the routine care sample for comparison. In
both the criminal justice and routine care samples, we
tested for possible non-linearity of the association be-
tween adherence and VL over the range of adherence
scores, using generalized additive models (GAMs) ad-
justed for age, sex, and study sample. To test whether
ART adherence differs by type of regimen used, we ex-
amined linear regression of Log VL on adherence, ad-
justed for age, sex, and study indicator, with main
independent variable the ART regimen type in the crim-
inal justice and routine care samples. Interaction P-
values were computed for the test of whether the regres-
sion coefficient for the given ART type is different than
that for NNRTI. Again, the routine care sample was ana-
lyzed to provide a normative comparison for the size
and direction of effects estimated in the criminal justice
sample for all analyses.
Effect modification
CD4 cell count and self-reported general health status
were assessed as possible effect modifiers of the
adherence-VL association in both the criminal justice
and routine care samples. CD4 count was dichotomized
as ≤ 500 vs. > 500+ cells/mm3, and self-reported general
health status was categorized as high (excellent, very
good, good) vs. low (fair, poor). To test whether the as-
sociations between adherence and VL differed signifi-
cantly by CD4 or health status strata, we conducted
linear mixed effect regressions of log-VL outcomes on
10% increments of adherence, age, sex, study site, the ef-
fect modifier variable of interest (either CD4 or self-
reported general health status, depending on the model)
and the interaction of adherence*effect modifier variable.
Table 2 Sociodemographic and Clinical Characteristics of
People Living with HIV in Criminal Justice Settings (STTR) and in
Routine Clinical Care (CNICS) Study Samplesa
Sample Characteristics STTR (%) (Range)b CNICS (%)
N 414 11,698
Mean age [SD] 44 [10] 46 [11]
Male 71 (45–100) 84
Race/Ethnicity
White 13 (0–22)*** 48
Black 73 (39–100)*** 34
Hispanic 9 (0–60) 14
Completed High School 62 (50–72) NA
Homeless 36 (0–66) NA
Drug Usec 74 (48–100)*** 37
Binge Alcohol Use 35 (13–56) 32
HIV VL ≥200d 26 (15–56)*** 11
Log (VL + 1) (mean [SD]) 4.3 [2.7] *** 3.6 [2.0]
VAS Adherence ≥95%e 59 (39–88)*** 71
VAS Adherence (mean % [SD]) 88 [20] *** 92 [16]
NNRTI-based regimen 31 (29–41) 29
Protease inhibitor
(PI)-based regimen
53 (24–60)*** 25
Integrase inhibitor-based
(INSTI) regimen
5 (3–15)*** 22
Combination/Other regimen 11 (9–20)*** 23
Included study timeframe 2011–2015f 2007–2017
Significant differences in mean values (e.g., age) and proportions between
STTR and CNICS characteristics indicated by: * P < 0.05, **P < 0.01, ***P < 0.001
aExcept IMPACT, where the week 2 VL and VAS adherence values were used
bRange of values across 7 included criminal justice-involved studies
cIncludes Cocaine/crack, opiates, methamphetamines, and marijuana
d VL = viral load
eVAS = visual analogue scale of adherence - % of ART medications taken in
prior 30 days
fDate range of baseline data collection
SD = standard deviation
STTR – Seek Test, Treat, Retain NIDA-funded criminal justice-involved
harmonized sample
CNICS - Centers for AIDS Research Network of Integrated Clinical Systems
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A sensitivity analysis using different cut points to define
the health status strata (excellent/very good vs. good/
fair/poor) was also performed, and because the results
did not differ greatly, we present results using the ori-
ginal cut-point.
Results
Descriptive characteristics
Comparing 414 criminal justice-involved people living
with HIV from STTR with 11,698 persons in routine
HIV care from CNICS (Table 2), the criminal justice-
involved persons were significantly (all comparisons sig-
nificant with P < 0.001) more likely to have a detectable
VL (26% vs. 12%), greater mean log-VL, smaller propor-
tion with ART adherence scores ≥ 95% (59% vs. 70%),
and smaller proportions of ART regimens containing
either PI (28% vs. 41%) or NNRTI (23% vs. 42%), or
INSTI regimens (5% vs. 22%; Table 2). Furthermore, the
criminal justice sample was comprised of a greater pro-
portion of Blacks (73% vs. 30%) and a greater proportion
of participants with substance use disorders (73% vs.
50%) than the persons in routine HIV care.
Associations of VAS adherence with viral load
We examined the association between VL (both con-
tinuous and binary) and adherence (in 10% increments)
using mixed effects regression analyses and found,
among the criminal justice sample the relative VL was
0.73 (95% CI = 0.65, 0.83; p < 0.01; Fig. 1a) indicating that
each 10% increment in adherence was associated with a
reduction in VL of 27% (1-relative VL%). Similarly in
the routine care sample, the relative VL was 0.66
(95% CI = 0.64, 0.68; p < 0.01), so each 10% increment
in adherence was associated with a reduction in VL
of 34%.
The interaction analysis indicated that the coefficients
in the two samples were not significantly different from
one another (P = 0.087). Similarly in the criminal justice
sample, for the logistic regression of binary detectable
VL on 10% increments of adherence we found an odds
ratio (OR) of 0.77 (95% CI = 0.69, 0.87; P < 0.01 Fig. 1b),
and in the routine care sample it was 0.69 (95% CI =
0.67, 0.71; P < 0.01). In this case, however, there was a
significant interaction, indicating that the coefficients in
the two samples were significantly different from one
another (P = 0.049). Moreover, we examined the associa-
tions of optimal adherence (≥95%) with binary detectable
VL, and in the criminal justice sample we found that the
OR was 0.56 (95% CI = 0.34, 0.92; P = 0.02; Fig. 1c), while
in the routine care sample the corresponding OR was
0.26 (95% CI = 0.23, 0.29; P = 0.01; P-value for the inter-
action = 0.0034; Fig. 1c). In the criminal justice sample,
Fig. 1 Associations of Adherence* with Viral Load Using Different Parameterizations,& among Criminal Justice-Involved (STTR)@ and Routine
Clinical Care (CNICS) Study Samples. Footnotes: *Adherence measured in 10% increments of the VAS in a and b. & Linear and logistic mixed
effects models adjusted for age in the criminal justice samples and linear and logistic models in the routine clinical care sample of continuous
adherence with: a log-transformed viral load and b. binary detectable viral load and c. binary detectable viral load with adherence dichotomized
at ≥95% vs. <95% adherence. Relative VL is the ratio of the VL of those with 10% higher adherence compared to the VL of those with 10% lower
adherence. @ Except New Hope, because the sample size with values (n=8) was too small for an estimate in b and c
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we further examined the associations of adherence with
both continuous log-VL and binary detectable VL using
generalized additive models ([GAM]; Fig. 2a & b) and
found that the relationship was fairly linear over the
range of adherence scores. The GAM analysis also ap-
peared to be approximately linear and with similar slope
over the range of adherence scores among people living
with HIV in routine clinical care (Fig. 2c & d).
Potential effect modification of associations of VAS
adherence with VL
In the analysis of the association between adherence and
VL in the criminal justice sample stratified by CD4
count, we found that the linear coefficients for the re-
gression of Log-VL on 10% VAS adherence, stratified by
CD4 count, was − 0.51 (95% CI -0.73, − 0.29; P = < 0.001)
for those with CD4 < 500; it was − 0.25 (95% CI -0.51,
0.02; P = 0.07) for those with CD4 ≥ 500 (Table 3). How-
ever, these coefficients were not significantly different
from one another in the interaction analysis for the
criminal justice sample (P = 0.14; Table 3). The corre-
sponding CNICS sample coefficient point estimates,
stratified by CD4, were similar to those in the criminal
justice sample, but with the much larger sample size in
routine care the interaction by CD4 level was significant
(P < 0.001; Table 3). In the stratified analysis by self-re-
ported general health status in the criminal justice sample,
we found that the coefficient for log-VL regressed on ad-
herence was much larger for low health status (− 0.44;
95% CI -0.70, − 0.18; P = 0.001) than it was for high health
status (0.01; 95% CI -0.25, 0.27; P = 0.90) and that the
interaction was significant (P = 0.01; Table 4). In the rou-
tine care sample, the corresponding linear coefficients for
the regression of Log-VL on 10% increments of adherence,
stratified by self-reported general health status showed no
significant interaction by health status (Table 4).
Association of ART regimens with viral suppression
Although there were no significant differences by regi-
men in the association of adherence with viral sup-
pression every other regimen compared with NNRTI
showed a significantly stronger association with viral
suppression (Table 5). Moreover, the interaction analysis
shows that both PIs (P < .004) and combination/other
ART regimens showed significantly stronger associations
than with NNRTI regimens.
Discussion
Among criminal justice-involved persons living with
HIV from seven criminal justice-focused studies in
STTR, we found consistent associations between higher
self-reported ART adherence, using a variety of ap-
proaches, with lower VL levels. We compared these
Fig. 2 Linearity of Associations between Adherence and Viral Load over the range of Adherence Scores in Criminal Justice-Involved (STTR)
Compared with Routine Clinical Care Samples (CNICS)@. Footnotes: @ Generalized Additive Model (GAM), adjusted for age and sex, of the
Association of Adherence with: a Centered Log-VL in the criminal justice sample; b Centered Log Odds of Binary VL in the criminal
justice sample; c Centered log-VL in the routine care sample; and d Centered Log Odds of Binary VL in the routine care sample. P-values
for A=0.4, B=0.8, C<0.001, D<0.001
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findings to people living with HIV in routine clinical
care from seven CNICS sites across the US and found
similar patterns of association. In addition, the coeffi-
cients reflecting the strength of the association were
generally in the same direction and of similar magnitude
to those among people living with HIV in the routine
clinical care sample. These findings have important im-
plications for the care of people living with HIV who
cycle through criminal justice settings, and the study of
ART adherence in the continuum of HIV care among
criminal justice-involved populations. Because criminal
justice-involved populations, particularly those recently
released from incarceration, are highly transient and
hard-to-reach because of frequent unstable housing,
substance use, and mental health problems they face
greater challenges to ART adherence as well as to acces-
sing HIV care [35–37]. Suitably, the findings support the
use of a simple, VAS measure to assess self-reported
ART adherence in criminal justice-involved populations.
Its brevity, ease of administration, and interpretation make
it attractive for use with low literacy populations such as
the criminal justice-involved people living with HIV [13].
Of particular note, in the criminal justice sample we
found that the associations of self-reported adherence
with VL were robust in that there was a significant asso-
ciation of high levels of adherence with lower levels of
VL, measured in a variety of ways – continuous (log-VL)
and dichotomous. It is clinically useful to know that
every 10-point increment on the 0–100% adherence
scale is associated with approximately a 25–30% decre-
ment in log-VL. The GAM analysis suggests that this as-
sociation was not significantly different in magnitude at
the low or high end of the VAS adherence scale. To-
gether these findings mean that assessing self-reported
ART adherence could be useful in detecting patients
who are most likely to have uncontrolled viremia at the
low end, as well as in detecting those who are likely well
controlled at the high end of adherence reports. Com-
parisons of these associations with the routine care sam-
ple provided strong confirmation of the findings in the
smaller criminal justice sample because in almost every
analysis, the coefficients were of very similar direction
and magnitude as those in routine care.
The examination of potential effect modification by
CD4 cell count and general health status also enhanced
the clinical relevance of our findings. In the criminal
justice sample, the regression coefficients relating high
levels of ART adherence with lower levels of VL were
significant in both strata of CD4 count, and the inter-
action testing difference in the association by CD4 level
was not significant, suggesting that the relationship held
Table 3 Associations of Adherenced with Log- viral load, Stratified by CD4 Count Level among Criminal Justice-Involved (STTR) and
Routine Clinical Care (CNICS) Study Samplesa
Coeff 95% CI P-value Interaction P-value1
STTR N = 208b
STTR Overall − 0.42 − 0.62,-0.22 < 0.001 NA
CD4 < 500 (n = 129) − 0.51 − 0.73, − 0.29 < 0.001 0.14
CD4≥ 500 (n = 79) − 0.25 − 0.51, 0.02 0.07 Ref
CNICS N = 9487c
CNICS Overall − 0.43 − 0.47, − 0.39 < 0.001 NA
CD4 < 500 (n = 4229) − 0.57 − 0.62, − 0.51 < 0.001 < 0.001
CD4≥ 500 (n = 5258) − 0.18 − 0.21, − 0.14 < 0.001 Ref
1Interaction P-value for the test of whether the regression coefficient for CD4 < 500 is different than that for CD4 ≥ 500
aLinear regression of Log VL on adherence, adjusted for age, sex, and study indicator, stratified by CD4 count level in the criminal justice and routine care samples
bn = 206 had missing CD4 values
cn = 2211 had missing CD4 values
dAdherence measured in 10% increments of the VAS
Table 4 Associations of Adherence with Log- Viral Load,
Stratified by Self-Reported Health Status (HS) in Criminal Justice-
Involved (STTR) and Routine Clinical Care (CNICS) Samplesa
Coeff 95% CI P-value Interaction
P-value1
STTR N = 196b
STTR Overall −0.28 − 0.50,-0.07 0.008 NA
Low HS (n = 78) −0.44 −0.70, − 0.18 0.001 0.01
High HS (n = 118) 0.01 −0.25, 0.27 0.935 Ref
CNICS N = 291c
CNICS Overall −0.31 −0.51, − 0.11 0.002 NA
Low HS (n = 68) −0.37 −0.62, − 0.11 0.005 0.59
High HS (n = 223) −0.26 −0.56, 0.04 0.084 Ref
1Interaction P-value tests whether the regression coefficient for CD4 < 500 is
different than CD4 ≥ 500
aLinear regression of Log-VL on 10% increments of VAS adherence, adjusted
for age, sex, and study indicator, stratified by self-reported general health
status in STTR and CNICS study samples
bMissing n = 218 because some studies didn’t use the self-reported general
health status item
cMissing n = 11,407 because some studies didn’t use the self-reported general
health status item
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regardless of stage of illness. However, the point-
estimate of this regression coefficient among those with
CD4 level < 500 was twice as large as that among those
with CD4 level ≥ 500. Furthermore in the routine care
sample, the point-estimate of this regression coefficient
among those with CD4 level < 500 was more than three
times as large as that among those with CD4 level ≥ 500.
Thus, with the large sample size the interaction test-
ing differences in the association by CD4 level was
highly significant. It is important that the association
was strongest among those with the most advanced
disease, and for whom clinicians would be most con-
cerned. Nonetheless, the regression coefficients relat-
ing high levels of ART adherence with lower levels of
VL were significant in both strata of CD4 count in
the routine clinical care sample, supporting the ro-
bustness of the association.
Examination of the associations by self-reported gen-
eral health status, however, did reveal more variation.
Among the criminal justice sample, we found that the
regression coefficients relating high levels of ART adher-
ence with lower levels of VL was strong and highly sig-
nificant among those with low self-reported general
health status levels. However, the corresponding coeffi-
cient was quite weak (nearly zero) and non-significant
among those with high self-reported health status levels.
Thus, the interaction testing of the difference in the as-
sociation by self-reported general health status level was
highly significant. This finding supports the association
among the most symptomatic, but not among those in
best self-perceived health. Interestingly, the same pattern
was not observed in the routine care sample. There we
found the association of VAS adherence with VL was
significant and of similar magnitude regardless of self-
reported general health status levels, so the interaction
was not significant. Moreover, we found that adherence
was associated with viral suppression, especially for com-
bination ART medications.
As with all studies, these analyses had several limita-
tions. First, this study was cross-sectional and hence we
can only report associations and cannot demonstrate
causality. We restricted the criminal justice and routine
clinical care samples to only those whose 30-day adher-
ence report window covered the VL test date. While this
restriction reduced the sample size substantially,
whether the VL overlapped with the adherence time-
frame would most likely impart random error, rather
than systematic bias in one consistent direction. Inher-
ent to smaller sample size is the reduced power of some
analyses, especially the interaction or moderation ana-
lyses, such as those we conducted by CD4 and self-
reported general health status. As often occurs with sec-
ondary data analyses, the data were collected for other
purposes and hence did not always align with the design
needs of this analysis. The smaller sample size resulting
from our attempts to eliminate error reduced our power
to detect associations and interactions, widening confi-
dence intervals around the coefficients of associations.
The sample size was also smaller for analysis by CD4
count and general health status than that for other vari-
ables, so we had limited power for these moderation
analyses. We lacked data on barriers to adherence, or
objective measures such as MEMs, pill count or number
of pills in each ART regimen to make comparisons with
Table 5 Associations of Adherenced with Log- viral load, Stratified by ART Type among Criminal Justice-Involved (STTR) and Routine
Clinical Care (CNICS) Study Samplesa
Mean VASc Coeff 95% CI P-value Interaction P-value1
STTR N = 234b
STTR Overall 87 −0.17 − 0.37,0.03 0.09 NA
NNRTI (n = 72) 86 −0.16 −0.47, 0.14 0.30 Ref
PI (n = 125) 89 −0.21 −0.52, 0.10 0.18 0.82
INSTI (n = 12) 87 0.55 −0.43, 1.53 0.27 0.17
Other/Combo (n = 25) 78 −0.31 −0.77, 0.14 0.18 0.60
CNICS N = 11,698
CNICS Overall 92 −0.42 −0.45, − 0.38 < 0.001 NA
NNRTI (n = 3347) 94 − 0.28 − 0.35, − 0.21 < 0.001 Ref
PI (n = 2979) 90 − 0.42 −0.49, − 0.35 < 0.001 0.004
INSTI (n = 2626) 93 − 0.35 − 0.42, − 0.27 < 0.001 0.20
Combination/Other (n = 2746) 91 − 0.51 −0.58, − 0.43 < 0.001 < 0.001
1Interaction P-value for the test of whether the regression coefficient for the given ART type is different than that for NNRTI
aLinear regressions of Log VL on adherence, adjusted for age, sex, and study indicator, stratified by ART type in the criminal justice and routine care samples
bn = 180 had missing ART type
cMean VAS was not significantly different by regimen in STTR (p = 0.08), and was significantly different by regimen in CNICS (p < 0.001)
dAdherence measured in 10% increments of the VAS
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the VAS. Despite these limitations in the data we do
have viral load data that a strong anchor for adherence
for this analysis. Last, although this study includes sev-
eral major HIV epicenters around the US, and both jail
and prison settings, the findings may not generalize to
all criminal justice settings, nor to all major metropol-
itan or smaller areas. It also may not generalize to cases
where the time frames of the VAS adherence and VL
measures do not match.
Conclusions
Overall, we found that relationships between adherence
and VL, using a variety of approaches among criminal
justice-involved PLWH, were robust and similar to those
in routine clinical care. Consequently, the VAS adherence
measure is a convenient, valid and useful adherence meas-
ure to support treatment for criminal justice-involved
people living with HIV who are vulnerable to falling out of
care. While we recognize that obtaining VL is essential to
assessing the outcomes of care, the VAS adherence meas-
ure is useful to clinicians in this situation, where it is often
difficult to measure VL regularly. It can provide results
more quickly and efficiently for clinical decision-making
than more complex adherence measures, or VL tests
which often take days to produce results. Findings from
this assessment when adherence is suboptimal (<=95%)
can direct clinical care in two important ways: 1) providers
can quickly intervene to optimize adherence and possibly
avoid virologic failure sooner than they could if they
waited for VL test results and 2) proactively order HIV-1
genotyping to assess for virologic resistance to current
medications. The latter is indicated because the risk of re-
sistance is greater with poor or intermittent adherence
that often attends criminal justice-involved people living
with HIV who have prevalent substance use disorders and
cycles of incarceration and release. This study also pro-
vides further evidence of the validity of the VAS adher-
ence measure for use in other survey research. This is,
particularly the case in post-release criminal justice-
involved populations or other situations where more ob-
jective forms of adherence measurement and more fre-
quent VL testing are not feasible. While some research
has supported the notion that criminal justice-involved
populations can achieve HIV continuum of care mile-
stones as well as those of non-criminal justice-involved
populations [38], it is generally recognized that criminal
justice-involved populations are at particular risk of lack-
ing HIV care and adherence to ART [7, 39–41]. Gaps in
care and loss of viral control often occur after release,
when it would be impractical and cost-prohibitive to
measure VL frequently or to monitor adherence with
resource-intensive approaches, such as MEMS-caps [42,
43]. Thus, our finding that the magnitude of association
between adherence to ART and VL was quite comparable
to that in a sample of people living with HIV in routine
clinical care was reassuring of the usefulness and robust-
ness of the VAS adherence measure for use in other low
resource settings. Future research should further examine
the performance of adherence measures in additional
hard-to-reach, disadvantaged populations.
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